The FDA has approved label changes for once-monthly Sublocade, helping to reduce possible barriers to treatment initiation for opioid use disorder and speed up availability of treatment, according to a press release from the manufacturer.
16h
Hosted on MSNFDA approves first opioid-free painkiller in over two decadesThe U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to severe acute pain in more than 20 years.
FDA officials have identified nine more companies allowed to manufacture and export a banned, lethal drug combination linked to the opioid crisis in West Africa. While seven companies never produced the drug,
Indivior said the U.S. Food and Drug Administration approved label changes for its opioid-dependence treatment Sublocade, including a rapid initiation protocol and alternative injection sites.
The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive like opioids.
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a growing number of alternative approaches. Their ultimate uptake, however, remains to be seen.
Here to help break down this new painkiller is Dr. Sean Mackey. He’s a Professor of Anesthesiology and Medicine at Stanford and Chief of the Division of Pain Medicine at the university. Dr. Mackey, welcome to Science Friday.
The Federal Drug Administration last month approved Journavx, a new kind of non-addictive pain medication. Doctors say Journavx is an important alternative because the power of opioids helped fuel an overdose epidemic and a surge in fentanyl use.
Indivior PLC (Nasdaq/LSE: INDV), a global leader in addiction treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved label changes for SUBLOCADE® including a rapid initiation protocol and alternative injection sites,
On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid
2d
GlobalData on MSNGLP-1RAs and opioid use disorder: a new frontier in addiction treatmentWhile medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they remain underutilised, says Rong Xu, PhD, professor at Case Western Reserve University and an expert in addiction research.
AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still believes in the promise of its candidate as Vertex Pharmaceuticals’ first-in-class drug Journavx opens up the non-opioid space.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results